Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xingnaojing and Naoxueshu for Acute Hemorrhagic Stroke
NCT04946474Phase 4Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2019
- Primary completion
- Jul 2020
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in intracerebral hemorrhage (ICH) comparing Xingnaojing + Naoxueshu with Placebo (2 arms). Primary endpoint: Self-care ability at 90 days. Status: unknown.
02
Drugs
Xingnaojingnaoxueshu
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT04946474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946474.